Sudarshan Pharma Industries Ltd
We refer to email dated 18/May/2026, referring to discrepancies in financial results for the QUARTER and financial year ended 31/March/2026.
We hereby submit the financial results for ....
RESULTS
● No Immediate Change
MEDIUM RISK
📅 Filed on BSE: 04 Jun 2026, 06:09 PM IST · BSE ID: aee44d19-a7cb-4c58-9bb7-0564179d6191
View Original BSE Filing (PDF)
💡
In Simple Terms
Sudarshan Pharma refiled its financial results for the last quarter and full year to correct errors from its first submission.
🤖 AI Summary
- Sudarshan Pharma Industries resubmitted audited financial results for the quarter and financial year ended March 31, 2026.
- The resubmission addresses discrepancies identified in the previous financial results filing dated April 30, 2026.
- Net Profit After Tax for the financial year ended March 31, 2026, was reported at Rs. 978.50 lakhs.
- Total revenue for the financial year ended March 31, 2026, stood at Rs. 50,249.34 lakhs.
- The company voluntarily adopted Indian Accounting Standards (Ind AS) for the first time from April 1, 2025.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Revenue for Year ended 31st March 2026
50,249.34 lakhs
Net Profit/(Loss) for Year ended 31st March 2026
978.50 lakhs
🏢 How This Affects the Company
The resubmitted results confirm a Net Profit/(Loss) After Tax of Rs. 978.50 lakhs and total revenue of Rs. 50,249.34 lakhs for the financial year ended March 31, 2026. This reconfirms the financial performance for the period.
The re-submission of financial results to address discrepancies indicates an effort to maintain compliance and accuracy in disclosures, potentially mitigating regulatory scrutiny.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this re-submission.
👤
Who Is Affected
All shareholders are affected by the company's financial transparency and accuracy. The re-submission provides confirmed financial figures for FY26, including Net Profit After Tax of Rs. 978.50 lakhs.
🔍
Management Signal
The re-submission indicates management's commitment to correcting reporting inaccuracies and ensuring compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Next quarterly results — evaluate consistent reporting accuracy.
Annual General Meeting minutes — review discussions on financial controls.
Any further clarifications from BSE — monitor regulatory correspondence.
MEDIUM RISK
Prior reporting discrepancies suggest potential internal control weaknesses that warrant monitoring.
💡 Investor Takeaway
Sudarshan Pharma Industries resubmitted its audited financial results for the quarter and financial year ended March 31, 2026, confirming a Net Profit After Tax of Rs. 978.50 lakhs and total revenue of Rs. 50,249.34 lakhs for FY26. This re-submission addresses prior discrepancies.
⚖️ Strengths & Concerns
✅ Positives
- Net Profit After Tax for the financial year ended March 31, 2026, was Rs. 978.50 lakhs, confirming profitability.
- Total revenue for the financial year ended March 31, 2026, reached Rs. 50,249.34 lakhs, demonstrating operational scale.
⚠️ Concerns
- The need to resubmit financial results due to initial discrepancies indicates a control issue in prior reporting processes.
- The prior year comparative period (FY25) for Net Profit After Tax was Rs. 1,402.77 lakhs, higher than current FY26 profit of Rs. 978.50 lakhs.
📅 Company Track Record
Sudarshan Pharma previously filed its audited financial statements for the quarter and financial year ended March 31, 2026, on April 30, 2026. This current filing is a resubmission responding to noted discrepancies.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What financial results did Sudarshan Pharma Industries resubmit?
Sudarshan Pharma Industries resubmitted its audited financial results for the quarter and financial year ended March 31, 2026.
What was Sudarshan Pharma Industries' Net Profit After Tax for FY26?
Sudarshan Pharma Industries reported a Net Profit After Tax of Rs. 978.50 lakhs for the financial year ended March 31, 2026.
What was Sudarshan Pharma Industries' total revenue for the financial year 2026?
Sudarshan Pharma Industries' total revenue for the financial year ended March 31, 2026, was Rs. 50,249.34 lakhs.
Why did Sudarshan Pharma Industries resubmit its financial results?
The financial results were resubmitted in response to an email from BSE dated May 18, 2026, referring to discrepancies in the previously filed financial results.
When did Sudarshan Pharma Industries adopt Ind AS?
Sudarshan Pharma Industries voluntarily adopted Indian Accounting Standards (Ind AS) for the first time beginning April 1, 2025.
Questions based on this BSE filing only. For information purposes.